Learning to Breathe: Optimizing Management of COPD Based on Device Selection

Kyle Copeland, PharmD
Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
This activity is supported by an educational grant from Mylan Specialty, LP.

Learning to Breathe: Optimizing Management of COPD Based on Device Selection

Kyle Copeland, PharmD
Clinical Pharmacist Specialist
Parkwest Medical Center
Knoxville, Tennessee



Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty
Kyle Copeland, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA; and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas
PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.


Educational Objectives

Upon completion of the educational activity, the participant should be able to:
  1. Review current treatment recommendations for chronic obstructive pulmonary disease (COPD).
  2. Examine currently available medication devices (eg, metered-dose inhalers, dry powder inhalers, nebulizers) in COPD and use of patient-specific factors in device selection.
  3. Explore the pharmacist's role in device section and assessing proper device use.
  4. Apply the COPD device algorithm to determine the best treatment modality for a given patient.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: April 10, 2013
Expiration date: April 10, 2015
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this lesson.


Related Articles
Vitamin D supplements can reduce the severity and duration of chronic obstructive pulmonary disease flare-ups by more than 40%.
In a study of patients with comorbid COPD and metabolic syndrome, elevated triglyceride levels were associated with increased mortality rates.
The FDA is reviewing a regulatory application to add an asthma indication to Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment, tiotropium bromide.
AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall’s respiratory franchise to the company.
Latest Issues
$auto_registration$